It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Diabetic kidney disease (DKD) is a major complication of diabetes. Expression of members of the microRNA (miRNA) miR-379 cluster is increased in DKD. miR-379, the most upstream 5′-miRNA in the cluster, functions in endoplasmic reticulum (ER) stress by targeting EDEM3. However, the in vivo functions of miR-379 remain unclear. We created miR-379 knockout (KO) mice using CRISPR-Cas9 nickase and dual guide RNA technique and characterized their phenotype in diabetes. We screened for miR-379 targets in renal mesangial cells from WT vs. miR-379KO mice using AGO2-immunopreciptation and CLASH (cross-linking, ligation, sequencing hybrids) and identified the redox protein thioredoxin and mitochondrial fission-1 protein. miR-379KO mice were protected from features of DKD as well as body weight loss associated with mitochondrial dysfunction, ER- and oxidative stress. These results reveal a role for miR-379 in DKD and metabolic processes via reducing adaptive mitophagy. Strategies targeting miR-379 could offer therapeutic options for DKD.
Kato, Abdollahi et al. identify a redox protein thioredoxin and mitochondrial fission-1 (FIS1) protein as miR-379 targets in mouse kidney. They find that miR-379 knockout mice are protected from diabetic kidney disease by enhancing mitophagy via FIS1, suggesting miR-379 as a potential therapeutic target for diabetic kidney disease.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Diabetes and Metabolism Research Institute, Caltech, Department of Diabetes Complications and Metabolism, Pasadena, USA (GRID:grid.20861.3d) (ISNI:0000000107068890)
2 Caltech, Transgenic Mouse Facility, Center for Comparative Medicine, Pasadena, USA (GRID:grid.20861.3d) (ISNI:0000000107068890)
3 Integrative Genomics Core, Caltech, Pasadena, USA (GRID:grid.20861.3d) (ISNI:0000000107068890)
4 Diabetes and Metabolism Research Institute, Caltech, Department of Diabetes Complications and Metabolism, Pasadena, USA (GRID:grid.20861.3d) (ISNI:0000000107068890); Irell and Manella Graduate School of Biological Sciences, Caltech, Pasadena, USA (GRID:grid.20861.3d) (ISNI:0000000107068890)
5 Caltech, Department of Cellular and Molecular Endocrinology, Pasadena, USA (GRID:grid.20861.3d) (ISNI:0000000107068890)
6 Caltech, Department of Cellular and Molecular Endocrinology, Pasadena, USA (GRID:grid.20861.3d) (ISNI:0000000107068890); Beckman Research Institute of City of Hope, Comprehensive Metabolic Phenotyping Core, Duarte, USA (GRID:grid.410425.6) (ISNI:0000 0004 0421 8357)
7 Caltech, Division of Biology and Biological Engineering, Pasadena, USA (GRID:grid.20861.3d) (ISNI:0000000107068890)